Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MBD1
REST API REST API
Homo sapiens
MBD1 is differentially expressed in 275 experiments: 126 organism parts: bone marrow, prostate, ... (124 more);, 199 disease states: normal, acute myeloid leukemia, ... (197 more);, 83 cell types 442 cell lines 33 compound treatments and 84 other conditions.
Synonyms PCM1, CXXC3
Orthologs Mbd1 (Rattus norvegicus)   Q2KIY8_BOVIN (Bos taurus)   MBD1 (2 of 2) (Danio rerio)   mbd1 (Danio rerio)   Mbd1 (Mus musculus)   CG3347 (Drosophila melanogaster)   MBD1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, negative regulation of transcription, DNA-dependent, protein binding, nuclear speck, regulation of transcription, DNA-dependent, cytoplasm, transcription corepressor activity, metal ion binding, methyl-CpG binding, heterochromatin, transcription from RNA polymerase II promoter, nucleus, chromosome, chromatin, zinc ion binding, sequence-specific DNA binding transcription factor activity
InterPro Term Methyl_CpG_DNA-bd, Znf_CXXC
UniProt Accession Q9UIS9, B4DXJ5, B4DI41
Search EB-eye ENSG00000141644
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-6573, E-GEOD-22541, E-MEXP-1251, E-MTAB-24, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, E-GEOD-4717, ... (37 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
A549
2
E-GEOD-6013, E-GEOD-3202
BT-474
2
E-GEOD-5823, E-GEOD-3529
K562
2
E-MTAB-37, E-GEOD-24147
MCF-7
2
E-GEOD-20081, E-GEOD-5823
T84
2
E-MTAB-37, E-GEOD-1474
436 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, E-GEOD-13909, ... (41 experiments)

Factor Value U/D Experiments
monocyte
2
E-GEOD-8286, E-GEOD-5099
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
testis - germ cell
2
E-AFMX-5, E-TABM-145
CD34+
2
E-TABM-145, E-AFMX-5
fibroblast
1
2
E-GEOD-26672, E-GEOD-3920, E-GEOD-3204
adult native RPE from 76 y.o. donor
1
E-GEOD-18811
77 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-MEXP-2280, E-MTAB-62, ... (57 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-4290
septic shock
2
E-GEOD-9692, E-GEOD-8121
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
chronic myelogenous leukemia
2
E-MTAB-62, E-GEOD-5550
cervical carcinoma
2
E-MTAB-62, E-MEXP-1331
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
193 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (21 experiments)

Factor Value U/D Experiments
mercaptopurine, methotrexate
1
E-GEOD-412
interleukin-4 (Homo sapiens)
1
E-GEOD-5099
interleukin-22 (Homo sapiens)
1
E-GEOD-7216
unknown
1
E-GEOD-7307
AMP
1
1
E-MEXP-2285
TGF
1
1
E-GEOD-15205
27 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-MEXP-2280, E-TABM-147, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Erbb2
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-6919

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-20847, E-MTAB-108, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, E-GEOD-22593, E-TABM-321, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-GEOD-22278, E-GEOD-10315, E-MEXP-1103, E-MEXP-1741, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (39 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (6 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-17636

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19743, E-GEOD-19069, E-GEOD-22541, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-22541, E-GEOD-1561, E-GEOD-4922, E-TABM-147

Processing time: 0.273 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM